1. Home
  2. FRST vs DMAC Comparison

FRST vs DMAC Comparison

Compare FRST & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Primis Financial Corp.

FRST

Primis Financial Corp.

HOLD

Current Price

$12.96

Market Cap

261.7M

Sector

Finance

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$7.88

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRST
DMAC
Founded
2004
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.7M
428.6M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
FRST
DMAC
Price
$12.96
$7.88
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.50
AVG Volume (30 Days)
99.5K
442.9K
Earning Date
01-27-2026
11-12-2025
Dividend Yield
2.88%
N/A
EPS Growth
N/A
N/A
EPS
0.34
N/A
Revenue
$138,816,000.00
N/A
Revenue This Year
$13.75
N/A
Revenue Next Year
$35.05
N/A
P/E Ratio
$40.91
N/A
Revenue Growth
33.08
N/A
52 Week Low
$7.59
$3.19
52 Week High
$13.94
$10.42

Technical Indicators

Market Signals
Indicator
FRST
DMAC
Relative Strength Index (RSI) 55.42 44.35
Support Level $12.95 $8.16
Resistance Level $13.88 $8.45
Average True Range (ATR) 0.42 0.50
MACD -0.06 -0.15
Stochastic Oscillator 4.06 6.03

Price Performance

Historical Comparison
FRST
DMAC

About FRST Primis Financial Corp.

Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: